Every Form 4 that Argan, Inc (AGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGX filings page.
Argan Inc. director and non-executive chairman William F. Griffin, Jr. reported an internal share transfer between his affiliated trusts. On December 5, 2025, 140,976 shares of Argan common stock were moved from the William F Griffin Jr. Revocable Trust to the William F Griffin 2025 GRAT Trust at a reported price of $0 per share. Following the transaction, the revocable trust no longer held these shares and the 2025 GRAT trust held 140,976 shares indirectly on his behalf.
Argan, Inc. insider William F. Griffin, Jr., a director and non-executive chairman, reported an internal trust-to-trust transfer of company stock. On December 1, 2025, he moved 5,000 shares of Argan common stock from the Griffin Family Trust to the William F. Griffin Jr. Revocable Trust at a stated price of $0. The filing states this resulted in no change in his overall beneficial ownership of Argan shares.
After the transaction, the Griffin Family Trust held 0 shares, while the William F. Griffin Jr. Revocable Trust held 140,976 shares indirectly for his benefit. An additional 11,650 shares were indirectly held through the Peach Pit Foundation, for which his wife serves as trustee. No derivative securities were reported.
Argan Inc. (AGX) director Peter W. Getsinger reported open‑market sales of the company’s common stock. He sold 2,000 shares at $292 on October 17, 2025 and 6,493 shares at $294.39 on October 20, 2025.
Following these transactions, he directly holds 9,897 shares of Argan common stock. The filing identifies him as a Director and lists the transactions as open‑market sales reported on a Form 4.
Argan, Inc. (AGX) director Peter W. Getsinger reported insider transactions on Form 4. On October 15, 2025, he exercised an option to purchase 10,000 shares at $46.35 per share using a net settle method, resulting in 8,493 shares acquired. That same day, he gifted 333 shares to each of his three children, totaling 999 shares. On October 16, 2025, he transferred 1,000 shares to a donor advised fund managed by Martha's Vineyard Investment Advisors.
Following these transactions, his directly held position was 18,390 shares. The option was originally awarded on January 11, 2018, became exercisable on January 11, 2019, and has an expiration date of January 11, 2028.
Argan, Inc. (AGX) reported insider activity by an officer on 10/15/2025. The reporting person exercised stock options to acquire 5,235 shares at $42.31 and 4,765 shares at $33.81, then conducted an open‑market sale of 10,000 shares at an average price of $309.37.
Following these transactions, the filer reported 21,006 shares of common stock held directly. The reporting person is identified as Chief Executive Officer, Gemma.
Argan, Inc. (AGX) insider activity: On October 13, 2025, a company officer exercised stock options and sold shares. The officer exercised 5,235 options at $43.10 and 4,765 options at $42.31, then sold 10,000 shares on the open market at an average price of $292.09. Following these transactions, the officer directly owned 21,006 common shares.
The reporting person is identified as an Officer (Chief Executive Officer, Gemma). The filing notes the transactions and resulting holdings, providing transparency into recent insider equity movements.
Argan Inc. (AGX): Director ownership change
Director James W. Quinn reported an internal transfer of 5,578 shares of Argan common stock on 10/10/2025, coded J, at a price of $0. The shares moved from the James W. Quinn 2025 GRAT No. 1 (indirect) to his direct ownership, which the report explains is a change in the form of beneficial ownership and not a sale.
Following the transactions, the filing shows 43,992 shares held indirectly via the GRAT and 5,578 shares held directly.
Director and CEO David H. Watson reported multiple stock transactions on 10/09/2025. He sold 4,441 shares on the open market at an average price of $277.01 per share and gifted 559 shares to the David and Laura Watson Foundation (a donor-advised fund). The Foundation then sold the 559 shares at $272.27 per share. After these reported transactions the filing shows the Reporting Person beneficially owned 47,132 shares directly.
ARGAN, Inc. director Cynthia A. Flanders reported a sale of 15,000 shares of common stock on 10/08/2025 at an average price of $271.96 per share. After the sale she beneficially owned 16,428 shares, held directly. The transaction was an open-market sale and reduced her direct stake but left a meaningful retained holding. The Form 4 is a routine Section 16 disclosure showing the timing, price, and remaining ownership following the sale.
James W. Quinn, a director of Argan Inc. (AGX), reported on Form 4 that he sold 13,444 shares of the issuer's common stock on September 30, 2025, at an average price of $269.12 per share. Following the sale, Mr. Quinn is reported to beneficially own 49,570 shares indirectly through the James W. Quinn 2025 GRAT No.1. The Form 4 is signed and dated October 1, 2025.
William F. Leimkuhler, a director of Argan Inc. (AGX), reported a sale of the issuer's common stock on October 1, 2025. The filing records a sale transaction with an average price of $274.73 per share and indicates the disposal of either 11,802 shares (table entry) or 11,806 shares (explanatory paragraph), with a reported remaining beneficial ownership of 38,834 shares following the transaction. The Form 4 is a routine Section 16 disclosure showing an open-market sale by an insider and lists the reporting persons Darien, CT address and role as a director. The filing does not include any option or derivative transactions.
ARGAN, Inc. (AGX) Form 4: The reporting person, John R. Jeffrey, Jr., sold 4,698 shares of ARGAN common stock on 09/29/2025 at an average price of $268.60 per share on the open market. After the sale he beneficially owns 4,556 shares directly and 8,000 shares indirectly through an IRA. The sale is reported on Form 4 and signed on 10/01/2025. The filing identifies Mr. Jeffrey as a director of the issuer and indicates the transaction was an open-market disposition.
Charles E. Collins IV, Chief Executive Officer of Argan, Inc. (AGX), reported option exercise and open-market sale on September 24, 2025. He exercised 5,000 shares from an option granted September 12, 2019, at an exercise price of $43.10 per share, and immediately sold 5,000 common shares on the open market at $267 per share. Following these transactions the Form 4 reports 26,006 shares beneficially owned after the exercise and 21,006 shares after the sale; the filing also records ownership of options underlying 5,000 shares and total derivative beneficial ownership of 39,735.
The Form 4 is signed and dated September 26, 2025, and identifies Collins as an officer (CEO). The filing documents standard Section 16 reporting of insider option exercise and subsequent disposition of shares.
Peter W. Getsinger, a director of Argan, Inc. (AGX), sold 1,000 shares of the company's common stock on September 19, 2025, on the open market at an average price of $264.54 per share. After the sale, Getsinger beneficially owned 11,896 shares directly. The Form 4 was signed on September 23, 2025, and lists Getsinger's Edgartown, MA address and director status. No derivative transactions or amendments are reported and the filing indicates this was a routine open-market disposition executed at the stated price.
Karen A. Sweeney, a director of ARGAN INC (AGX), reported a sale of company stock on September 19, 2025. She sold 390 shares of the issuer's common stock on the open market at a price of $264.25 per share and after the transaction beneficially owned 1,315 shares directly. The Form 4 was signed by the reporting person on September 22, 2025. The filing records the transaction type as an open-market sale and specifies direct ownership following the sale.
James W. Quinn, a director of Argan Inc. (AGX), disclosed open-market sales of the issuer's common stock on September 19 and September 22, 2025. He sold 11,897 shares on September 19 at an average price of $260.73 per share, leaving 4,660 shares held directly after that transaction. He then sold the remaining 4,660 shares on September 22 at an average price of $259.35 per share, leaving no direct holdings. The filing also shows indirect ownership of 63,014 shares through the James W. Quinn 2025 GRAT No.1. The transactions are reported on a Form 4 and were signed by Mr. Quinn on September 22, 2025.
Charles E. Collins IV, CEO of Argan, Inc. (AGX), reported option exercise and subsequent open-market sale on 09/18/2025. He exercised 7,500 shares of a stock option granted 09/12/2018 at an exercise price of $43.10 per share, and immediately sold 7,500 shares on the open market at $257.39 per share. Following these transactions the filing shows 21,006 shares beneficially owned directly and 44,735 shares underlying options/derivatives reported as beneficially owned. The Form 4 is signed and dated 09/22/2025.